| 奥希替尼治疗晚期肺腺癌1例并文献复习 |
| |
| 作者姓名： | 刘源 倪渐凤 刘丽娜 尹先哲 |
| |
| 作者单位： | 南阳市第二人民医院肿瘤科;南阳市第二人民医院肿瘤过继免疫疗法重点实验室 |
| |
| 摘 要： | 分析1例晚期肺腺癌患者应用第1代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)(吉非替尼)治疗耐药后的应用奥希替尼治疗的临床疗效及不良反应。患者应用吉非替尼治疗11个月出现耐药,后给予奥希替尼治疗28个月病情进展,期间未出现严重不良反应。奥希替尼治疗第1代EGFR-TKIs耐药后的晚期肺腺癌患者,临床疗效较好,不良反应少。
|
| 关 键 词： | 奥希替尼 耐药 晚期肺腺癌 |
Observation of clinical efficacy of osimertinib in advanced lung adenocarcinoma: A case report and literature review |
| |
| Authors: | LIU Yuan NI Jianfeng LIU Lina YIN Xianzhe |
| |
| Institution: | (Department of Oncology,Nanyang Second People’s Hospital,Nanyang Henan 473012,China;Key Laboratory of Adoptive Immunotherapy for Cancer,Nanyang Second People’s Hospital,Nanyang Henan 473012,China) |
| |
| Abstract: | We analyzed the clinical efficacy and adverse reactions of a patient with advanced lung adenocarcinoma who received resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)(gefitinib)for treatment with osimertinib,and review the relevant literature.The patient developed resistance after 11 months of treatment with first-generation EGFR-TKIs(gefitinib),and then received osimertinib for 28 months.There were no serious adverse reactions in the treatment of osimertinib.Osimertinib is effective in treating patients with advanced lung adenocarcinoma after resistance to first-generation EGFR-TKIs,with good clinical efficacy and fewer adverse reactions. |
| |
| Keywords: | osimertinib resistance advanced lung adenocarcinoma |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
